semaj83/ctmatch_classification huggingface dataset:
Patient description: The patient is a 15-year-old boy with asthma diagnosed a year ago. He presents with shortness of breath, chest tightening and cough. According to his mother, he didn't respond to the usual corticosteroid inhaler. He was admitted to the emergency department with diagnosis of severe asthma exacerbation. He is a candidate for general corticosteroid therapy. Spirometry revealed a forced expiratory volume in the first second (FEV1) of 60% of the predicted. His past medical history is non-significant. His family history is significant for asthma in his mother and his uncle. He used to be treated with combination of inhaled corticosteroids and Zafirlukast.

Clinical trial eligibility criteria: eligible ages (years): 5.0-20.0,  Duchenne Muscular Dystrophy Age 5-20 years Duchenne muscular dystrophy documented by written report of stop codon mutation analysis of the dystrophin gene Subject is capable of cooperating for efficacy and safety testing Absent dystrophin on muscle biopsy Subjects may be untreated, taking prednisone or comparable corticosteroids Subjects taking corticosteroids must be on the same dose for at least 3 months (90 days) prior to the start of the study  Known allergy to any aminoglycoside or sulfate compounds Current use of potential nephrotoxic or ototoxic drug Current use of corticosteroids has not been stable for 3 months (90) days Known mutation at nucleotide 1555 in 12S rRNA gene of mitochondrial DNA (predisposes to aminoglycoside hearing loss and commercially available via Athena Diagnostics Lab). This DNA testing (Hearing susceptibility test) will be made available through funding from this grant Inability to hear within the range of 0 to 25 dB in any hearing frequency by pure tone audiometry Cystatin C equal to or > 1.4mg/L Other medical condition that would impede the conduct of study (e.g., congestive heart failure)
Patient description: The patient is a 15-year-old boy with asthma diagnosed a year ago. He presents with shortness of breath, chest tightening and cough. According to his mother, he didn't respond to the usual corticosteroid inhaler. He was admitted to the emergency department with diagnosis of severe asthma exacerbation. He is a candidate for general corticosteroid therapy. Spirometry revealed a forced expiratory volume in the first second (FEV1) of 60% of the predicted. His past medical history is non-significant. His family history is significant for asthma in his mother and his uncle. He used to be treated with combination of inhaled corticosteroids and Zafirlukast.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Asthma Adults aged >= 18 years Patients with severe persistent allergic asthma with the following characteristics FEV1 (Forced Expiratory Volume in One Second) <80% of predicted Frequent daily symptoms (>=4 days/week on average) or nocturnal awakening (>=1/week on average) Multiple severe asthma exacerbations: either >=2 severe asthma exacerbations having required an unscheduled medical intervention with systemic corticosteroid in the past year, or hospitalization (including emergency room treatment) for an asthma exacerbation in the past year Despite a high dose inhaled corticosteroid >1000 mg beclomethasone dipropionate or equivalent and a inhaled long-acting B2-agonist With an allergy to a perennial allergen demonstrated with convincing i.e. positive prick skin test or in vitro reactivity to a perennial aeroallergen (RAST) Total serum IgE level >= 30 to <=700 IU/ml and suitable serum total IgE level and weight according to Xolair dosing tablets  Age < 18 years Smoking history > 20 pack years Patients who have had an asthma exacerbation during the 4 weeks prior to randomization History of food or drug related severe anaphylactoid or anaphylactic reaction Elevated serum IgE levels for reasons other than allergy (e.g. parasite infections, hyperimmunoglobulin E syndrome, Wiskott-Aldrich Syndrome or allergic bronchopulmonary aspergillosis) Patients with active cancer, suspicion of cancer or any history of cancer Pregnant women Known hypersensitivity to omalizumab or to one of its components Patients already treated with omalizumab (indeed a previous treatment with omalizumab could have modified the FceRI expression) Patients who had participated in a clinical trial in the past 3 months
Patient description: The patient is a 15-year-old boy with asthma diagnosed a year ago. He presents with shortness of breath, chest tightening and cough. According to his mother, he didn't respond to the usual corticosteroid inhaler. He was admitted to the emergency department with diagnosis of severe asthma exacerbation. He is a candidate for general corticosteroid therapy. Spirometry revealed a forced expiratory volume in the first second (FEV1) of 60% of the predicted. His past medical history is non-significant. His family history is significant for asthma in his mother and his uncle. He used to be treated with combination of inhaled corticosteroids and Zafirlukast.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  COPD Congestive Heart Failure Asthma Respiratory Distress Syndrome, Adult Pneumonia Starting on mechanical ventilation (including: invasive, noninvasive, CPAP or BiPAP for purpose of treatment of respiratory failure) years of age or older  Use of home mechanical ventilation, including nocturnal ventilation, continuous mechanical ventilation,BiPAP Continuous use of CPAP or BiPAP for treatment of obstructive sleep apnea Placed on mechanical ventilation for purposes of surgical anesthesia or use of anesthesia for a diagnostic procedure Patient has tracheostomy or was intubated endotracheally prior to admission
Patient description: The patient is a 15-year-old boy with asthma diagnosed a year ago. He presents with shortness of breath, chest tightening and cough. According to his mother, he didn't respond to the usual corticosteroid inhaler. He was admitted to the emergency department with diagnosis of severe asthma exacerbation. He is a candidate for general corticosteroid therapy. Spirometry revealed a forced expiratory volume in the first second (FEV1) of 60% of the predicted. His past medical history is non-significant. His family history is significant for asthma in his mother and his uncle. He used to be treated with combination of inhaled corticosteroids and Zafirlukast.

Clinical trial eligibility criteria: eligible ages (years): 5.0-56.0,  Asthma Patient Compliance (patient-level) Age 5-56 years Physician diagnosis of asthma Continuous HMO enrollment with prescription drug rider Electronic prescription of an inhaled corticosteroid  (patient-level) Diagnosis of chronic obstructive pulmonary disease Diagnosis of congestive heart failure (practice-level) Primary care practice (i.e., pediatrics, family practice, or internal medicine) within the health system. A practice is defined as a group of physicians who by virtue of speciality or geography care for a relatively contained population of patients and who cross-cover the care of these patients (practice-level) None
Patient description: The patient is a 15-year-old boy with asthma diagnosed a year ago. He presents with shortness of breath, chest tightening and cough. According to his mother, he didn't respond to the usual corticosteroid inhaler. He was admitted to the emergency department with diagnosis of severe asthma exacerbation. He is a candidate for general corticosteroid therapy. Spirometry revealed a forced expiratory volume in the first second (FEV1) of 60% of the predicted. His past medical history is non-significant. His family history is significant for asthma in his mother and his uncle. He used to be treated with combination of inhaled corticosteroids and Zafirlukast.

Clinical trial eligibility criteria: eligible ages (years): 45.0-90.0,  Lung Diseases Bronchitis, Chronic Male or female out-patients >/= 45 years Subjects suffering from chronic bronchitis FEV1</= 70% and FEV1/FVC </= 70% predicted from age, height and sex No documented episode of AECB (requiring treatment) within 6 weeks of randomization and not experiencing an exacerbation at the time of screening Sputum production on most days, even when exacerbation free Subjects presented with at least two documented (i.e. requiring antibiotics and/or systemic steroid administration) acute exacerbation episodes during the last 12 monthsIf receiving chronic therapy with inhaled long acting bronchodilators and/or inhaled or systemic steroids, the treatment must have remained stable for the preceding 6 weeks prior to screening Smoking history of at least 20 pack-years Subjects willing and able to give fully informed written consent  Subjects with contra-indications to moxifloxacin Known bronchial carcinoma, pulmonary tuberculosis, cystic fibrosis, documented chronic bronchial asthma or diffuse bronchiectasis Subjects who are actively participating in intensive pulmonary rehabilitation programs Subjects with a known history of chronic colonization of pathogenic organisms resistant to moxifloxacin, e.g. Pseudomonas spp, MRSA No systemic or inhaled antibiotic therapy during the 6 weeks prior to screening and any long term antibiotic usage Subjects requiring home ventilatory support for COPD and those who have a tracheostomy in situ (subjects requiring home/potable oxygen therapy or CPAP for sleep apnea can be included)
Patient description: The patient is a 15-year-old boy with asthma diagnosed a year ago. He presents with shortness of breath, chest tightening and cough. According to his mother, he didn't respond to the usual corticosteroid inhaler. He was admitted to the emergency department with diagnosis of severe asthma exacerbation. He is a candidate for general corticosteroid therapy. Spirometry revealed a forced expiratory volume in the first second (FEV1) of 60% of the predicted. His past medical history is non-significant. His family history is significant for asthma in his mother and his uncle. He used to be treated with combination of inhaled corticosteroids and Zafirlukast.

Clinical trial eligibility criteria: eligible ages (years): 18.0-70.0,  Asthma Documented clinical history of asthma Forced expiratory volume in 1 second between 60% and 90% of predicted Using an inhaled corticosteroid (ICS)at a dose equivalent to 200 to 500 mcg daily of beclomethasone (BDP)or equivalent combined with a long-acting beta-2-agonist or an ICS alone at a dose equivalent to >500 to 1000mcg daily of BDP daily  Lower respiratory tract infection within 1 month of study entry Use of systemic corticosteroids within 1 month of study entry Smoking history of 10 pack years or more Changes in regular asthma therapy within 12 weeks of study entry Any significant disorder that in the investigator's opinion might put the patient at risk or influence the study outcomes
Patient description: The patient is a 15-year-old boy with asthma diagnosed a year ago. He presents with shortness of breath, chest tightening and cough. According to his mother, he didn't respond to the usual corticosteroid inhaler. He was admitted to the emergency department with diagnosis of severe asthma exacerbation. He is a candidate for general corticosteroid therapy. Spirometry revealed a forced expiratory volume in the first second (FEV1) of 60% of the predicted. His past medical history is non-significant. His family history is significant for asthma in his mother and his uncle. He used to be treated with combination of inhaled corticosteroids and Zafirlukast.

Clinical trial eligibility criteria: eligible ages (years): 12.0-75.0,  Asthma Patients with a history of severe allergic asthma who completed the treatment period of CIGE250011E3 protocol, without experiencing any significant drug-related adverse events Male or female patients 12-75 years of age who have given written informed consent approved by the ethical committee  Patients who had not received study medication for greater than 84 days since visit 38 of study CIGE240011E3 Pregnant females or nursing mothers Patients with know hypersensitivity to any ingredients of Omalizumab or related drugs Other protocol-defined inclusion/
Patient description: The patient is a 15-year-old boy with asthma diagnosed a year ago. He presents with shortness of breath, chest tightening and cough. According to his mother, he didn't respond to the usual corticosteroid inhaler. He was admitted to the emergency department with diagnosis of severe asthma exacerbation. He is a candidate for general corticosteroid therapy. Spirometry revealed a forced expiratory volume in the first second (FEV1) of 60% of the predicted. His past medical history is non-significant. His family history is significant for asthma in his mother and his uncle. He used to be treated with combination of inhaled corticosteroids and Zafirlukast.

Clinical trial eligibility criteria: eligible ages (years): 0.0-999.0,  Hypogonadotropic Hypogonadism Kallmann Syndrome Puberty, Delayed Puberty, Precocious GnRH Deficiency Failure to go through a normal, age-appropriate, spontaneous puberty, and abnormal hormone levels OR Children with abnormally early development of puberty (Precocious Puberty) OR Family members of these patients  pituitary tumor high prolactin levels
Patient description: The patient is a 15-year-old boy with asthma diagnosed a year ago. He presents with shortness of breath, chest tightening and cough. According to his mother, he didn't respond to the usual corticosteroid inhaler. He was admitted to the emergency department with diagnosis of severe asthma exacerbation. He is a candidate for general corticosteroid therapy. Spirometry revealed a forced expiratory volume in the first second (FEV1) of 60% of the predicted. His past medical history is non-significant. His family history is significant for asthma in his mother and his uncle. He used to be treated with combination of inhaled corticosteroids and Zafirlukast.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Asthma for and TALC Studies Clinical history consistent with asthma Forced expiratory volume in one second (FEV1) greater than 40% of predicted value Asthma confirmed by one of the following two 1. Beta-agonist reversibility to 4 puffs albuterol of at least 12% OR 2. Methacholine provocative concentration at 20% (PC20) FEV1 of 8 milligrams per millimeter (mg/mL) or less when not on an inhaled corticosteroid, or 16 mg/mL or less when on an inhaled corticosteroid Need for daily controller therapy (i.e., inhaled corticosteroids, leukotriene modifiers, and/or long-acting beta-agonists) based on one or more of the following 1. Received prescription for or used asthma controller within the 12 months prior to study entry OR 2. Experienced symptoms for more than twice a week and not on asthma controller If on inhaled steroids (any drug at any dose not exceeding the equivalent of 1000 micrograms (mcg) of fluticasone daily), participant must have been on a stable dose for at least 2 weeks prior to study entry Non-smoker (i.e., total lifetime smoking history less than 10 pack-years; no smoking for at least 1 year prior to study entry) Willing to use an effective form of birth control throughout the study for Study Ability to measure peak expiratory flow (PEF) each morning using the electronic peak flow meter (EPFM) device and to accurately transcribe the PEF measurements onto the diary cards at least 75% of the time during the last 2 weeks of the adherence testing period compliance with recording peak flow measurements and symptoms in a symptom diary during the last 2 weeks of the adherence testing period  for and TALC Studies Lung disease other than asthma, including chronic obstructive pulmonary disease (COPD) and chronic bronchitis Established or suspected diagnosis of vocal cord dysfunction Significant medical illness other than asthma History of respiratory tract infection within the 4 weeks prior to study entry History of a significant exacerbation of asthma within the 4 weeks prior to study entry History of life-threatening asthma requiring treatment with intubation and mechanical ventilation in the 5 years prior to study entry Hyposensitization therapy other than an established maintenance regimen Inability to coordinate use of the delivery devices used in the study, based on the opinion of the investigator or clinical coordinator Pregnant
Patient description: The patient is a 15-year-old boy with asthma diagnosed a year ago. He presents with shortness of breath, chest tightening and cough. According to his mother, he didn't respond to the usual corticosteroid inhaler. He was admitted to the emergency department with diagnosis of severe asthma exacerbation. He is a candidate for general corticosteroid therapy. Spirometry revealed a forced expiratory volume in the first second (FEV1) of 60% of the predicted. His past medical history is non-significant. His family history is significant for asthma in his mother and his uncle. He used to be treated with combination of inhaled corticosteroids and Zafirlukast.

Clinical trial eligibility criteria: eligible ages (years): 12.0-999.0,  Asthma Patient with poorly controlled asthma  Patient under age of 12 Not possessing a mobile phone and who don't have adequate command of the English language
Patient description: The patient is a 15-year-old boy with asthma diagnosed a year ago. He presents with shortness of breath, chest tightening and cough. According to his mother, he didn't respond to the usual corticosteroid inhaler. He was admitted to the emergency department with diagnosis of severe asthma exacerbation. He is a candidate for general corticosteroid therapy. Spirometry revealed a forced expiratory volume in the first second (FEV1) of 60% of the predicted. His past medical history is non-significant. His family history is significant for asthma in his mother and his uncle. He used to be treated with combination of inhaled corticosteroids and Zafirlukast.

Clinical trial eligibility criteria: eligible ages (years): 0.0-999.0,  Asthma Moderate to severe asthma with suboptimal control  Intermittent or mild asthma, patient with good asthma control
Patient description: The patient is a 15-year-old boy with asthma diagnosed a year ago. He presents with shortness of breath, chest tightening and cough. According to his mother, he didn't respond to the usual corticosteroid inhaler. He was admitted to the emergency department with diagnosis of severe asthma exacerbation. He is a candidate for general corticosteroid therapy. Spirometry revealed a forced expiratory volume in the first second (FEV1) of 60% of the predicted. His past medical history is non-significant. His family history is significant for asthma in his mother and his uncle. He used to be treated with combination of inhaled corticosteroids and Zafirlukast.

Clinical trial eligibility criteria: eligible ages (years): 6.0-18.0,  Allergic Asthma allergic asthma since > 6 months equal or lower corticosteroid therapy before study entry FEV1>50%  severe asthma respiratory infection within the last 4 weeks smoking
Patient description: The patient is a 15-year-old boy with asthma diagnosed a year ago. He presents with shortness of breath, chest tightening and cough. According to his mother, he didn't respond to the usual corticosteroid inhaler. He was admitted to the emergency department with diagnosis of severe asthma exacerbation. He is a candidate for general corticosteroid therapy. Spirometry revealed a forced expiratory volume in the first second (FEV1) of 60% of the predicted. His past medical history is non-significant. His family history is significant for asthma in his mother and his uncle. He used to be treated with combination of inhaled corticosteroids and Zafirlukast.

Clinical trial eligibility criteria: eligible ages (years): 18.0-55.0,  Asthma Male or female (medically or surgically postmenopausal or practicing an accepted form of barrier or hormonal contraception) subjects age 18-55 Stable, mild atopic asthma with forced expiratory volume in one second (FEV1) greater than 70% of predicted for age and height, and not requiring any medical treatment other than short acting inhaled beta2-agonists as required or for those on steroids, taking < 1000 mcg of inhaled corticosteroid per day No recent or significant history of cigarette smoking (no smoking within six months prior to entry into the study; less than 10 pack-years cumulative history of cigarette smoking) Signed written informed consent to participate in the study; ability to return to the clinic for repeated visits No history of asthma exacerbations or acute intercurrent respiratory illness (viral respiratory syndrome, bronchitis, pneumonia) for a four week period preceding entry into the screening phase of the study Subjects who take inhales steroids regularly must demonstrate reproducibility to inhaled mannitol (PD15<1.0 doubling doses) during a 2 week run-in period A PD15 to the mannitol challenge < 315mg  Significant gastrointestinal (including hepatic), hematological, cardiovascular, cerebrovascular, metabolic such as including type II diabetes or other body system disorder Regular consumption of fish consisting more than 1 meal of fish per week or regular fish oil supplements during the trial and for at least 2 weeks prior to the first study visit Subjects who have taken oral corticosteroids or a leukotriene receptor antagonist in 4 weeks prior to entry into the study Psychosis, alcoholism, active substance abuse, or any personality disorder, which would make compliance with this protocol problematic Pregnant or nursing females Any other medical or social condition which, in the opinion of the investigator, could confound the interpretation of the data derived from this study Subjects taking >1000 mcg of inhaled steroids daily in those subjects taking inhaled steroids Subjects requiring regular anti-histamines for allergies Subjects who have allergy to fish or any other ingredient in the study products Subjects using anti-coagulants (warfarin, heparin)
Patient description: The patient is a 15-year-old boy with asthma diagnosed a year ago. He presents with shortness of breath, chest tightening and cough. According to his mother, he didn't respond to the usual corticosteroid inhaler. He was admitted to the emergency department with diagnosis of severe asthma exacerbation. He is a candidate for general corticosteroid therapy. Spirometry revealed a forced expiratory volume in the first second (FEV1) of 60% of the predicted. His past medical history is non-significant. His family history is significant for asthma in his mother and his uncle. He used to be treated with combination of inhaled corticosteroids and Zafirlukast.

Clinical trial eligibility criteria: eligible ages (years): 18.0-50.0,  Asthma Male or female patient with a working diagnosis of asthma by clinical presentation or by spirometry testing results Currently prescribed inhaled corticosteroids (ICS) for the treatment of asthma, and may or may not be prescribed additional therapies for asthma Is a current smoker with a minimum of a five year history of smoking Provides written informed consent  Has a diagnosis of COPD Is currently enrolled in another clinical trial Has any condition which, may decrease the chance of obtaining satisfactory data to achieve the objectives of the study Is unable to provide written informed consent